Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | GBA1 | P04062 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | MANBA | O00462 | 2/20 | 0.47 |
| ▸ | IDUA | P35475 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | GUSB | P08236 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PYGB | P11216 | 2/20 | 0.37 |
| ▸ | PYGL | P06737 | 1/20 | 0.37 |
| ▸ | PYGM | P11217 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconolactone SCHEMBL18465607 | 1.00 | LMNA (1.00) | LMNAGBA1HIF1AMANBAIDUA | |
| Gluconolactone SCHEMBL333412 | 1.00 | LMNA (1.00) | LMNAGBA1HIF1AMANBAIDUA | |
| Gluconolactone SCHEMBL2466472 | 1.00 | LMNA (1.00) | LMNAGBA1HIF1AMANBAIDUA | |
| Gluconolactone SCHEMBL7148519 | 1.00 | LMNA (1.00) | LMNAGBA1HIF1AMANBAIDUA | |
| Gluconolactone SCHEMBL17068350 | 1.00 | LMNA (1.00) | LMNAGBA1HIF1AMANBAIDUA | |
| Gluconolactone SCHEMBL15631270 | 1.00 | LMNA (1.00) | LMNAGBA1HIF1AMANBAIDUA | |
| Gluconolactone SCHEMBL24637666 | 1.00 | LMNA (1.00) | LMNAGBA1HIF1AMANBAIDUA | |
| Gluconolactone SCHEMBL15631261 | 1.00 | LMNA (1.00) | LMNAGBA1HIF1AMANBAIDUA | |
| Gluconolactone SCHEMBL15631260 | 1.00 | LMNA (1.00) | LMNAGBA1HIF1AMANBAIDUA | |
| Gluconolactone SCHEMBL2464302 | 1.00 | LMNA (1.00) | LMNAGBA1HIF1AMANBAIDUA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016083790-A1 | PROCESS FOR THE PREPARATION OF CANAGLIFLOZIN | CIPLA LIMITED (IN) | 2016-06-02 | — | — | WO | disclosed |
| US-8222219-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20110237789-A1 | PROCESSES FOR PREPARING OF GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZENE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237526-A1 | METHOD FOR THE PREPARATION OF A CRYSTALLINE FORM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-29 | — | — | US | disclosed |
| US-7943788-B2 | Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20090233874-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | Tanabe Pharma Corporation (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | LMNA 1887/4885GBA1 56/4885HIF1A 479/4885 |
| US-20090233874-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | SLC5A1, SLC5A2, SI | LMNA 3879/4885GBA1 294/4885HIF1A 1750/4885 |
| US-20110237789-A1 | PROCESSES FOR PREPARING OF GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZENE DERIVATIVES | UGGT1, B3GAT3, UGT1A3 | LMNA 1593/4885GBA1 16/4885HIF1A 876/4885 |
| US-20110237526-A1 | METHOD FOR THE PREPARATION OF A CRYSTALLINE FORM | CYP2F1, CYP4B1, GANAB | LMNA 1387/4885GBA1 6/4885HIF1A 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.